WASHINGTON – Danaher Corporation announced Thurs. that Danaher has entered into a definitive agreement to acquire privately-held Aldevron, for a cash purchase price of approximately $9.6 billion.
Founded in 1998 by Michael Chambers and John Ballantyne, Aldevron is headquartered in Fargo and employs approximately 600 people. Aldevron manufactures high-quality plasmid DNA, mRNA, and proteins, serving biotechnology and pharmaceutical customers across research, clinical and commercial applications. Aldevron will operate as a standalone operating company and brand within Danaher’s Life Sciences segment.
Rainer M. Blair, Danaher President and Chief Executive Officer, said, “We are thrilled to have Aldevron join Danaher’s Life Sciences segment. For nearly 25 years, Aldevron has made tremendous contributions to the advancement of cell, gene and other novel therapies and vaccines. This acquisition will expand our capabilities into the important field of genomic medicine and help us support our customers and their critical mission to bring more life-saving therapies and vaccines to market faster.”
The transaction is subject to customary conditions, including receipt of applicable regulatory approvals.
Comments